Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. reported second-quarter 2026 sales of $16,607 million, up 5% from $15,806 million, with Pharmaceutical sales of $14,760 million and Animal Health sales of $1,775 million, both up 5% and 8%, respectively. Growth was led by oncology and cardiometabolic products, including KEYTRUDA/KEYTRUDA QLEX at $8,366 million and WINREVAIR at $588 million, up 75%.
The company recorded a GAAP net loss of $1,335 million (EPS $(0.54)) and a non-GAAP net loss of $330 million (EPS $(0.13)), versus GAAP EPS of $1.76 and non-GAAP EPS of $2.13 a year earlier. Results were driven by a $5.7 billion R&D charge for the acquisition of Terns Pharmaceuticals, equal to $2.31 per share, which also pushed non-GAAP R&D to $9.7 billion.
Merck highlighted major regulatory milestones, including FDA approval of LIPFENDRA, multiple new KEYTRUDA-based regimens, and additional vaccine indications. For full-year 2026, it raised sales guidance to $66.3–$67.3 billion but cut non-GAAP EPS guidance to $2.66–$2.76 from $5.04–$5.16, reflecting one-time acquisition charges of $9.0 billion for Cidara and $5.7 billion for Terns.
Seidman Christine E reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Christine E. Seidman reported a routine compensation-related award of 63.2296 phantom stock units on June 30, 2026 at a reference value of $128.5000 per unit, increasing her phantom stock balance to 21,291.2690 units. She also reported direct ownership of 100 shares of common stock. The phantom stock units are cash-settled on a 1-for-1 basis in accordance with Merck’s deferred compensation plan after her service ends.
Karsanbhai Surendralal Lanca reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Karsanbhai Surendralal Lanca reported a routine compensation grant of phantom stock units and updated share holdings. The filing shows an award of 126.4591 phantom stock units tied on a 1‑for‑1 basis to Merck common stock. These phantom units are to be settled entirely in cash after the director’s termination of service, under the company’s Plan for Deferred Payment of Directors' Compensation.
Following this grant, Lanca holds 5,518.8018 phantom stock units and 1 share of Merck common stock directly. The transactions do not involve any open‑market buying or selling of Merck shares and reflect non‑cash, deferred director compensation.
Merck & Co., Inc. director Mary Ellen Coe reported a routine compensation-related transaction involving phantom stock units. She received a grant of 233.4630 phantom stock units at a reference price of $128.5000 per unit, recorded as a grant or award acquisition.
Following this grant, Coe holds 31,999.1016 phantom stock units, each tied on a 1-for-1 basis to Merck common stock but settled 100% in cash upon her termination of service under the Plan for Deferred Payment of Directors' Compensation. Separately, she directly holds 10 shares of Merck common stock after the reported transactions.
Warden Kathy J reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Kathy J. Warden reported a compensation-related update rather than an open-market trade. She received a grant of 1,853.0997 phantom stock units tied 1-for-1 to Merck common stock at a reference value of $118.7200 per unit, bringing her phantom stock holdings to 17,890.2917 units. These units will be settled entirely in cash after her service ends, under the Plan for Deferred Payment of Directors' Compensation. Separately, she reported direct ownership of 500 shares of Merck common stock, which includes shares accumulated through dividend reinvestment transactions.
Karsanbhai Surendralal Lanca reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Karsanbhai Surendralal Lanca reported a compensation-related award of phantom stock units rather than an open-market trade. On 2026-05-29, he received 1,853.0997 phantom stock units, bringing his total phantom stock holdings to 5,392.3427 units.
Each phantom unit is linked on a 1-for-1 basis to Merck common stock but will be settled 100% in cash after his service ends, following a distribution schedule under the Plan for Deferred Payment of Directors' Compensation. He also reports direct ownership of 1 share of Merck common stock, with holdings including shares from dividend reinvestment transactions.
Merck & Co., Inc. director Mary Ellen Coe reported a routine compensation-related change in holdings. She received a grant of 1,853.0997 phantom stock units, each on a 1-for-1 basis referencing Merck common stock. These phantom units are to be settled 100% in cash upon her termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After the grant, she holds 31,765.6386 phantom stock units and 10 shares of Merck common stock, with share holdings including amounts acquired through dividend reinvestment transactions.
Merck & Co., Inc. director Inge G. Thulin reported updated holdings that include a new grant of phantom stock units. On 2026-05-29, the director acquired 1,853.0997 phantom stock units, each linked on a 1-for-1 basis to Merck common stock. These phantom units are designed as deferred compensation and will be settled 100% in cash after the director’s termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After this grant, the director holds 27,469.7107 phantom stock units and 2,932.8610 shares of common stock, with the common stock holdings including shares acquired through dividend reinvestment transactions.
Seidman Christine E reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Christine E. Seidman reported a compensation-related change in her holdings. She received an award of 1,853.0997 phantom stock units tied to Merck common stock at a reference price of $118.72 per unit. After this grant, her phantom stock balance is 21,228.0394 units, which will be settled 100% in cash after her service ends under the company’s deferred compensation plan. Separately, she reports holding 100 shares of Merck common stock directly, including shares accumulated through dividend reinvestment.
RUSSO PATRICIA F reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Patricia F. Russo received 1,853.0997 phantom stock units as a grant of deferred compensation tied to Merck common stock. The phantom stock units are to be settled 100% in cash upon her termination of service under the Plan for Deferred Payment of Directors' Compensation. After this award, she holds 62,390.7517 phantom stock units and 13,148 shares of Merck common stock directly.